ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,738.52
-1.78%
US Tech 100
19,620.80
-2.29%
Dow Jones
42,579.08
-0.99%
Brent Oil
69.34
0.00%
Bitcoin
86,860.73
-3.43%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Delcath Systems Inc (DCTH) Quote

Delcath Systems Inc

Delcath Systems Inc (DCTH)

NASDAQ
13.22
-0.21
(-1.56%)
Closed March 06 4:00PM
Delayed by 15 minutes
12.76
-0.46
(-3.48%)
After Hours: 7:02PM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
12.76
Bid
12.80
Ask
13.87
Volume
866,436
11.56 Day's Range 13.51
3.70 52 Week Range 16.97
Market Cap
407.985M
Previous Close
13.43
Open
12.96
Last Trade
20
@
13.87
Last Trade Time
Financial Volume
$ 11,156,276
VWAP
12.8761
Average Volume (3m)
393,164
Shares Outstanding
31,973,784
Dividend Yield
-
PE Ratio
-8.85
Earnings Per Share (EPS)
-1.49
Revenue
2.07M
Net Profit
-47.68M

About Delcath Systems Inc

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product candidate, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System, or Melphalan/HDS, is designed to administer high-dose chemotherapy... Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product candidate, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System, or Melphalan/HDS, is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Show more

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Website
www.delcath.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Delcath Systems Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker DCTH. The last closing price for Delcath Systems was $13.43. Over the last year, Delcath Systems shares have traded in a share price range of $ 3.70 to $ 16.97.

Delcath Systems currently has 31,973,784 shares outstanding. The market capitalization of Delcath Systems is $429.41 million. Delcath Systems has a price to earnings ratio (PE ratio) of -8.85.

Ask ADVFN Intelligence (AI)

Delcath Systems (DCTH) Options Flow Summary

DCTH Options Flow

Overall Flow

Bullish

Net Premium

29k

Calls / Puts

100.00%

Buys / Sells

100.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

DCTH Latest News

More News

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Edgar (US Regulatory)
14 hours ago
DCTH (-1.56%)

Form 8-K - Current report
Edgar (US Regulatory)
15 hours ago
DCTH (-1.56%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 07 2025
DCTH (-1.56%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 07 2025
DCTH (-1.56%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 07 2025
DCTH (-1.56%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 07 2025
DCTH (-1.56%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 07 2025
DCTH (-1.56%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 07 2025
DCTH (-1.56%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.82-12.482853223614.5814.612.6235867213.69673286CS
4-3.61-22.052535125216.3716.9712.6232028514.99071332CS
120.443.5714285714312.3216.9710.7539316413.92704016CS
262.3422.456813819610.4216.978.0837372911.91394966CS
528.8222.2222222223.9616.973.73226819.84482459CS
1566.65108.837970546.1116.972.253531366.52434935CS
2608.99238.4615384623.7725.182.252540057.40122675CS

DCTH - Frequently Asked Questions (FAQ)

What is the current Delcath Systems share price?
The current share price of Delcath Systems is $ 12.76
How many Delcath Systems shares are in issue?
Delcath Systems has 31,973,784 shares in issue
What is the market cap of Delcath Systems?
The market capitalisation of Delcath Systems is USD 429.41M
What is the 1 year trading range for Delcath Systems share price?
Delcath Systems has traded in the range of $ 3.70 to $ 16.97 during the past year
What is the PE ratio of Delcath Systems?
The price to earnings ratio of Delcath Systems is -8.85
What is the cash to sales ratio of Delcath Systems?
The cash to sales ratio of Delcath Systems is 204.33
What is the reporting currency for Delcath Systems?
Delcath Systems reports financial results in USD
What is the latest annual turnover for Delcath Systems?
The latest annual turnover of Delcath Systems is USD 2.07M
What is the latest annual profit for Delcath Systems?
The latest annual profit of Delcath Systems is USD -47.68M
What is the registered address of Delcath Systems?
The registered address for Delcath Systems is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Delcath Systems website address?
The website address for Delcath Systems is www.delcath.com
Which industry sector does Delcath Systems operate in?
Delcath Systems operates in the SURGICAL,MED INSTR,APPARATUS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
PSTVPlus Therapeutics Inc
$ 1.46
(317.14%)
359.59M
AGMHAGM Group Holdings Inc
$ 0.213
(108.21%)
694.71M
LZMHLZ Technology Holdings Ltd
$ 9.79
(33.56%)
590.5k
TNXPTonix Pharmaceuticals Holding Corporation
$ 14.62
(33.39%)
16.07M
GVVisionary Holdings Inc
$ 4.89
(32.34%)
135.24M
BLNEEastside Distilling Inc
$ 0.7846
(-89.40%)
12.25k
ACONAclarion Inc
$ 1.5501
(-77.86%)
51.53M
ELABPMGC Holdings Inc
$ 0.7132
(-42.02%)
1.51M
SNBRSleep Number Corporation
$ 7.49
(-41.89%)
4.56M
CCLDCareCloud Inc
$ 2.0904
(-33.00%)
1.23M
AGMHAGM Group Holdings Inc
$ 0.213
(108.21%)
694.71M
PSTVPlus Therapeutics Inc
$ 1.46
(317.14%)
359.59M
NVDANVIDIA Corporation
$ 110.57
(-5.74%)
321.25M
GVVisionary Holdings Inc
$ 4.89
(32.34%)
135.24M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 10.75
(-11.38%)
134.95M

DCTH Discussion

View Posts
Filterthenoise Filterthenoise 9 months ago
Straight 🔥 $DCTH
👍️0
Monksdream Monksdream 9 months ago
DCTH under $10
👍️0
Filterthenoise Filterthenoise 10 months ago
$DCTH strong
👍️0
Monksdream Monksdream 11 months ago
DCTH 10Q due 3/26
👍️0
Filterthenoise Filterthenoise 1 year ago
$DCTH
👍️0
Filterthenoise Filterthenoise 1 year ago
Lets go $DCTH
👍️0
green maschine green maschine 2 years ago
6 now. That was quick.
👍️0
TheFinalCD TheFinalCD 2 years ago
5.80 HI :0)
👍️0
green maschine green maschine 2 years ago
The 5 analysts offering 12-month price forecasts for Delcath Systems Inc have a median target of 18.00, with a high estimate of 22.00 and a low estimate of 13.00. The median estimate represents a +216.62% increase from the last price of 5.69.
👍️0
dande1990 dande1990 2 years ago
H.C. Wainwright Reaffirms Their Buy Rating on Delcath Systems (DCTH)

TipRanks

 Aug. 15, 2023, 09:35 AM

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Delcath Systems (DCTH – Research Report), with a price target of $18.00. The company’s shares opened today at $5.84.
👍️0
dande1990 dande1990 2 years ago
HC Wainwright & Co. Maintains Delcath Systems (DCTH) Buy Recommendation

Story by George Maybach • 14h

?

Fintel reports that on August 15, 2023, HC Wainwright & Co. maintained coverage of Delcath Systems (NASDAQ:DCTH) with a Buy recommendation.
Analyst Price Forecast Suggests 436.15% Upside
As of August 2, 2023, the average one-year price target for Delcath Systems is 16.73. The forecasts range from a low of 10.10 to a high of $23.10. The average price target represents an increase of 436.15% from its latest reported closing price of 3.12.

👍️0
TheFinalCD TheFinalCD 2 years ago
5.13 LO :/


SO FAR
👍️0
green maschine green maschine 2 years ago
Hope you get that back working soon. I use TD Ameritrade and so far haven't had any problems with their system.
👍️0
dande1990 dande1990 2 years ago
No... On my app and my laptop I have a message saying they are unable to at the moment

$DCTH
👍️0
green maschine green maschine 2 years ago
Wow, bummer. Did they say why?
👍️0
dande1990 dande1990 2 years ago
Fidelity is down. Cant make trades at all.

$DCTH
👍️0
green maschine green maschine 2 years ago
Awesome! I need to get my correct my sleeping habits - kicking myself today.
👍️0
dande1990 dande1990 2 years ago
Ive been able to do 5.01 to 5.77 and 5.55 to 7.25. In again at 6.33.
👍️0
green maschine green maschine 2 years ago
Nice move CD. Still climbing. $$DCTH$$
👍️0
green maschine green maschine 2 years ago
I'm in at 5.43, went back to bed and missed the flip today. Oh well might see 10 by EOW.
👍️0
dande1990 dande1990 2 years ago
This board needs some life!! Lets go $DCTH
👍️0
TheFinalCD TheFinalCD 2 years ago
round ii

filled as low as 6.46 on that DIP

$DCTH
👍️0
TheFinalCD TheFinalCD 2 years ago
$7!!!!!!!!!!!!!!


SOLD SOME 6.95 AFTER 7 COULDNT BREAK HARD
👍️0
TheFinalCD TheFinalCD 2 years ago
6.70 LG!!!!!!
👍️0
SriMaharaj SriMaharaj 2 years ago
Told you guys. Get in now before it's too late.
👍️0
SriMaharaj SriMaharaj 2 years ago
Wait until it cross $6. You will see $10 today or tomorrow.
👍️0
TheFinalCD TheFinalCD 2 years ago
6.50 WAS A NICE POP OFF MY 5.55 ENTRY
👍️0
green maschine green maschine 2 years ago
Yeah there's resistance at that level, but I believe it'll break through today. Too much buying pressure here. FDA approval is huge news.
👍️0
Filterthenoise Filterthenoise 2 years ago
BOOM $DCTH
👍️0
TheFinalCD TheFinalCD 2 years ago
6.24 SO FAR BUT THEY QUICKLY SOLD IT OFF TO 5.34

DCTH
👍️0
Monksdream Monksdream 2 years ago
Early Barchart Top 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0
green maschine green maschine 2 years ago
Good morning. I wonder how high this flies today.
👍️0
TheFinalCD TheFinalCD 2 years ago
https://finviz.com/quote.ashx?t=DCTH&p=d

https://twitter.com/ripster47/status/1691258931300200448
👍️0
green maschine green maschine 2 years ago
Where is everybody?
👍️0
Carlito78 Carlito78 2 years ago
What ever happened to SamnotSamuel?
👍️0
harvest1 harvest1 2 years ago
Wow stock is down 2 weeks before PDUFA date. Hard to imagine this wont be approved this time with no adcom. Not sure why there arent more buyers. Hopefully there is a pop on approval and they have a quick launch and revenue ramp.
👍️0
Filterthenoise Filterthenoise 2 years ago
Finally! Go $DCTH
👍️0
Jmma Jmma 2 years ago
Finally looks promising for real. Had shares few years ago and got chewed up and spit out . Reverse splits wiped out a lot of investors. Looks like they turned the corner and could become the investment everyone hoped for awhile back. Good luck to those holding.
👍️0
Filterthenoise Filterthenoise 2 years ago
No one loving the start of the run?
👍️0
Filterthenoise Filterthenoise 2 years ago
Next leg time LFG $DCTH!!
👍️0
Filterthenoise Filterthenoise 2 years ago
$DCTH... LFG!
👍️0
Filterthenoise Filterthenoise 2 years ago
Let's GO!

$DCTH
👍️0
Filterthenoise Filterthenoise 2 years ago
Another run at it coming

GLTA
👍️0
harvest1 harvest1 2 years ago
A new corporate presentation was posted to the company's website with alot of updated information.
https://delcath.com/investors/events-presentations/

This company has been left for dead by the market but I think the stock could recover strongly next year after approval if revenues begin to roll in. I would be interested to hear others thoughts on catalysts and stock price targets. I think at least a $100 million market cap should be expected on approval. Longer term at least $250 million market cap when revenues are material. Starting 3 new trials in 2023 will be positive as well. There appears to be little interest or attention for the company now but hopefully that changes after approval. My biggest fear is that they will have to dilute more at these awful rock bottom prices.
👍️0
Filterthenoise Filterthenoise 3 years ago
Here we go...
👍️0
nealhugh nealhugh 3 years ago
just waiting.........................................................................
👍️0
nealhugh nealhugh 3 years ago
yup--- good chat with GA... TY. Neal
👍️0
nealhugh nealhugh 3 years ago
FDA submission Summer/Fall 2022
FDA approval possible within 6 mos of submission

Fund raise? when?

Stock price lousy so wait for the fund raise?

All results on trials and use are good!

TY, Neal
👍️0
nealhugh nealhugh 3 years ago
https://ih.advfn.com/p.php?pid=nmona&article=87441339
👍️0
nealhugh nealhugh 3 years ago
Yeah--- I had Covid so I have been delayed!!! :)
👍️0

Your Recent History

NASDAQ
DCTH
Delcath Systems
LSE
0A7O
Microstrategy
LSE
ZR46
Hsbc Bk. 27
NASDAQ
RKLB
Rocket Lab USA
LSE
CCUA
Ubs Cmci Carry
GATE
LAMBETH
Lambda
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads